At the news
? NEUTRALIMPACT 2/10 PRESS-RELEASE filed Nov 2, 2026 at 16:35 ET
MiNK Therapeutics announced it will report Q3 2026 financial results on November 11, 2026, before market open. The press release provides no financial data, only a forward-looking update on clinical programs for agenT-797 and strategic collaborations. Consensus estimates are EPS -$0.50 and revenue $875K, but no actual results are disclosed yet.
- Q3 2026 earnings release scheduled for November 11, 2026 before market open
- Conference call and webcast at 8:30 AM ET on November 11, 2026
- No financial results disclosed in this press release
- Consensus estimates: EPS -$0.50, revenue $875K (2 analysts)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access